Medscape

Chronic Myeloid Leukemia Highlights From ASH 2025

Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic ...
The American Journal of Managed Care

CLL Followed by CML: A Rare Case Described

A very unusual case of 2 chronic leukemias, chronic lymphocytic leukemia (CLL) and secondary chronic myeloid leukemia (CML) existing simultaneously in an older patient was treated with a pair of ...
Medscape

TKI Therapy Affects Quality of Life in CML Patients

Patients with chronic myeloid leukemia (CML) who are being treated with tyrosine kinase inhibitors (TKIs) have significant adverse effects and quality-of-life issues that need to be addressed, ...
Monthly Prescribing Reference

Combination of Asciminib Plus a TKI Offers Hope of Treatment-Free Remission in CML

With the combination of asciminib plus a TKI, 91% of CML patients had attained a major molecular response by month 36. Combining asciminib, a first-in-class BCL::ABL1 inhibitor, with a tyrosine kinase ...
Seeking Alpha

Enliven Therapeutics Maybe Improving Kinase Inhibitors, But Too Early To Tell The Impact

Enliven Therapeutics is a biotech specializing in targeted therapies for cancer, with two main pipeline projects. ELVN-001 is an inhibitor of BCR-ABL, targeting a mutation that causes resistance to ...
Business Wire

Xspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients and greater than expected negative effects on the bioavailability of ...

STOCKHOLM--(BUSINESS WIRE)--Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a Swedish pharmaceutical company which uses its innovative Hynap technology to develop 505(b)(2) improved versions of ...
ascopubs.org

Health-Related Quality of Life and Financial Burden in Ethiopian Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Study

Global Disparities in the Characteristics and Outcomes of Leukemia Clinical Trials: A Cross-Sectional Study of the ClinicalTrials.gov Database Health-related quality of life (HRQoL) is now an ...
Business Insider

ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% ...